One Month Follow-up of Haemostatic Variables in Patients Undergoing Aortocoronary Bypass Surgery
暂无分享,去创建一个
L. Mannucci | E. Tremoli | P. Biglioli | C. Antona | L. Salvi | L. Mussoni | A. Parolari | P. Gerometta | P. Gerometta
[1] P. Mannucci,et al. Poor Comparability of Prothrombin Fragment 1 + 2 Values Measured by Two Commercial ELISA Methods: Influence of Different Anticoagulants and Standards , 1994, Thrombosis and Haemostasis.
[2] D. Nilsen,et al. Lipopolysaccharide Induced Monocyte Thromboplastin Synthesis and Coagulation Responses in Patients Undergoing Coronary Bypass Surgery after Preoperative Supplementation with n-3 Fatty Acids , 1993, Thrombosis and Haemostasis.
[3] H. Philippou,et al. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[4] A. Michelson,et al. Aprotinin reduces cardiopulmonary bypass‐induced blood loss and inhibits fibrinolysis without influencing platelets , 1993, British journal of haematology.
[5] S. Brister,et al. Thrombin Generation during Cardiac Surgery: Is Heparin the Ideal Anticoagulant? , 1993, Thrombosis and Haemostasis.
[6] S. Downing,et al. Release of vasoactive substances during cardiopulmonary bypass. , 1992, The Annals of thoracic surgery.
[7] B. Hunt,et al. Aprotinin and Heparin Monitoring During Cardiopulmonary Bypass , 1992, Circulation.
[8] A. Lusky,et al. Aprotinin Prevents Cardiopulmonary Bypass‐Induced Platelet Dysfunction: A Scanning Electron Microscope Study , 1992, Circulation.
[9] H. Teufelsbauer,et al. Early Activation of Hemostasis during Cardiopulmonary Bypass: Evidence for Thrombin Mediated Hyperfibrinolysis , 1992, Thrombosis and Haemostasis.
[10] J. Soria,et al. Hemostasis in Patients Undergoing Extracorporeal Circulation: The Effect of Aprotinin (Trasylol) , 1991, Thrombosis and Haemostasis.
[11] H. Teufelsbauer,et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. , 1991, The Journal of thoracic and cardiovascular surgery.
[12] J. Buring,et al. Antiplatelet therapy to prevent coronary artery bypass graft occlusion. , 1990, Circulation.
[13] J. Jespersen,et al. Enhanced Effective Fibrinolysis following the Neutralization of Heparin in Open Heart Surgery Increases the Risk of Post-Surgical Bleeding , 1990, Thrombosis and Haemostasis.
[14] F. Ofosu,et al. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D‐dimer and fibrinogen/fibrin fragment E antigen , 1990, British journal of haematology.
[15] H. Kwaan,et al. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation , 1986, American journal of hematology.
[16] A. S. Douglas,et al. Studies on the Anticoagulant Action of Aprotinin (“Trasylol”) , 1970, Thrombosis and Haemostasis.
[17] D. Royston. Coagulation in cardiac surgery. , 1996, Advances in cardiac surgery.
[18] J. Levy,et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1991, The Journal of thoracic and cardiovascular surgery.
[19] J. Chesebro,et al. Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion. , 1986, European heart journal.